Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Clinical trial NCT00129766 · COMPLETED

Trial details

NCT number: NCT00129766
Sponsor: MedImmune LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Respiratory Syncytial Virus Infections

Start date: 2004-11-01
Primary completion: 2006-05-01
Enrollment: 6635

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.